Medical control fees or affect the performance of pharmaceutical companies, a new round of market reshuffle is coming

Release time:


Medicine anti-corruption strikes again! A reporter from Guangzhou Daily learned that a few days ago, nine ministries and commissions, including the State Health and Family Planning Commission, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, jointly issued the "key points for the special management of 2015 to correct unhealthy tendencies in the purchase and sale of Medicine and Medical Services" (hereinafter referred to as "key points"). The top priority of this special action. From the industry's point of view, medical control fees may put pressure on the performance of pharmaceutical companies, and a new round of market reshuffle may come.
Purchase and sale of medicine
into the focus of anti-corruption rectification
According to the requirements of the document, the relevant departments will start from four aspects: strictly standardizing the purchase and sale of medicine, standardizing the behavior of medical services, strengthening the intensity of relevant reform, and strengthening the construction of industry discipline, so as to maintain a high-pressure situation and work together to carry out medical anti-corruption.
The regulation of pharmaceutical purchase and sale has become the focus of this time. It is reported that the regulation of pharmaceutical purchase and sale covers almost all aspects of the procurement process, including the supply of drugs and high-value consumables, centralized procurement of drugs in public hospitals, price negotiation mechanism for some drugs, sunshine procurement of high-value medical consumables, normal shortage of drug reserves, fixed-point production pilot of small varieties of basic drugs, supply of key small varieties of drugs, low-cost drugs, etc.
A new round of market reshuffle is coming
In addition, the promotion of medical institutions to control fees has also become a key direction. The "Key Points" proposes to improve medical services, carry out medical quality, fee and cost monitoring, and promote medical institutions to control fees.
Some industry observers said that the impact of medical control fees on the performance of pharmaceutical companies is not small, and is universal. "Tenders are pressing drug prices, and medical control fees are also reducing the clinical use of drugs, especially high-priced drugs; on the other hand, the liberalization of drug prices also means that a price war may begin. For many small and medium-sized pharmaceutical companies with poor strength, low brand market share and serious product homogeneity, the future may be increasingly difficult." It said that controlling costs for the product side may mean that a new round of market reshuffle in the industry is coming. Traditional pharmaceutical companies may need to change their channel strategies and strengthen the value of their products to conduct differentiated competition. With the advancement of hospital fee control rules, the follow-up effect will gradually appear, and it is necessary for enterprises to adjust their product structure or product research and development to keep up with policy changes.